FMP

FMP

Enter

ARGX.BR - argenx SE

Financial Summary of argenx SE(ARGX.BR), argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of aut

photo-url-https://financialmodelingprep.com/image-stock/ARGX.BR.png

argenx SE

ARGX.BR

EURONEXT

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

358 EUR

5.5 (1.54%)

About

ceo

Mr. Timothy Van Hauwermeiren EMBA, M.B.A., M.Sc.

sector

Healthcare

industry

Biotechnology

website

https://www.argenx.com

exchange

EURONEXT

Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-...

CIK

N/A

ISIN

NL0010832176

CUSIP

N0610Q109

Address

Willemstraat 5

Phone

31 10 703 8441

Country

NL

Employee

1,148

IPO Date

Jul 10, 2014

Summary

CIK

-

Exchange

EURONEXT

Industry

Biotechnology

Sector

Healthcare

CUSIP

N0610Q109

ISIN

NL0010832176

Country

NL

Price

358

Beta

0.35

Volume Avg.

61.16k

Market Cap

21.28B

Shares

-

52-Week

271.0-494.1

DCF

0

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-74.74

P/B

-

Website

https://www.argenx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest ARGX.BR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep